Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Merck
McKinsey
Harvard Business School
Boehringer Ingelheim

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SIMBRINZA

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Simbrinza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01937299 ↗ Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® Completed Alcon Research Phase 4 2013-10-01 The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy (TRAVATAN Z®).
NCT01937312 ↗ Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue Completed Alcon Research Phase 4 2013-10-01 The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy.
NCT01978600 ↗ Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 4 2013-10-01 The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.
NCT02167035 ↗ Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) Completed Allergan Phase 4 2014-08-01 To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.
NCT02167035 ↗ Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) Completed Cornerstone Health Care, PA Phase 4 2014-08-01 To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.
NCT02419508 ↗ SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) Completed Alcon Research Phase 4 2015-08-07 The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.
NCT02730871 ↗ Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® Terminated Alcon Research Phase 4 2016-06-24 The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Simbrinza

Condition Name

Condition Name for Simbrinza
Intervention Trials
Ocular Hypertension 7
Open-Angle Glaucoma 3
Glaucoma 3
Open Angle Glaucoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Simbrinza
Intervention Trials
Glaucoma 7
Ocular Hypertension 7
Glaucoma, Open-Angle 6
Hypertension 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Simbrinza

Trials by Country

Trials by Country for Simbrinza
Location Trials
United States 5
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Simbrinza
Location Trials
Texas 3
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Simbrinza

Clinical Trial Phase

Clinical Trial Phase for Simbrinza
Clinical Trial Phase Trials
Phase 4 8
Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Simbrinza
Clinical Trial Phase Trials
Completed 7
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Simbrinza

Sponsor Name

Sponsor Name for Simbrinza
Sponsor Trials
Alcon Research 6
Allergan 1
Cornerstone Health Care, PA 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Simbrinza
Sponsor Trials
Industry 9
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.